author-photo

Joyce Steinberg

Astellas Pharma
Center for Global Development

62

Papers

966

Citations

Citation Trend

Filter By

Papers (39) Sort By

Journal Conference Others

The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer.

2021 Breast Cancer Research and Treatment
Show All
- Source
- Cite
- Save
Citations (1)
Overall survival (OS) and metastasis-free survival (MFS) by depth of prostate-specific antigen (PSA) decline in the phase III PROSPER trial of men with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide (ENZA).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region.

2021 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial

2021 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (5)
Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors: An updated analysis of EV-201 Cohort 2.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
746P EV-201: Long-term results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and PD-1/PD-L1 inhibitors

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (3)
685P A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC): Outcomes by prostate-specific antigen (PSA) response

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab in locally advanced or metastatic urothelial cancer.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
A Randomized Placebo-Controlled Phase 2 Trial Evaluating Exemestane With or Without Enzalutamide in Patients With Hormone Receptor-positive Breast Cancer.

2020 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (10)
Final overall survival (OS) from PROSPER: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC).

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (12)